- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
Non-Invasive Glucose Monitoring - Solianis Monitoring AG: Supported by the Zürich Cantonal Bank and the European Union
—
ZURICH, Switzerland, May 5ZURICH, Switzerland, May 5 /PRNewswire/ -- The research for non-invasive glucose monitoring has found new investors: The Zürich Cantonal Bank will invest in Solianis; together with a research grant from the European Union and private investors a total of CHF 2.5 Mio is raised.
Solianis Monitoring AG has reached another mile stone in its career: The company has concluded a capital increase of CHF 2.5 Mio. Alongside with private investors the Zürich Cantonal Bank will participate with CHF 500'000 as a part of their funding program for pioneer companies. "It is essential for us to support start-ups in the difficult fund raising process and be a reliable partner for the development of the company," says Herbert Huwiler, Start-up Finance, Zürich Cantonal Bank.
In addition, the Seventh Framework programme for Research and Technological Development (RP7/FP7), the main instrument of the EU to fund European research, supports the company with EUR 220'000 to continue its activities. Solianis has accomplished this in a project consortium with various European partners.
Mario Stark, CEO of Solianis Monitoring, concludes: "With this capital increase we can continue the current clinical work to demonstrate that our technology is applicable in the daily life of patients". Solianis Monitoring AG is developing a device for the non-invasive monitoring of blood glucose for patients with diabetes to improve their quality of life.
Contact: Mario Stark, CEO Phone: +41-44-306-80-40 Mobile: +41-79-542-88-74 E-Mail: mario.stark@solianis.com
Related news
Related News
- Solianis' Non-Invasive Glucose Monitor Tracks Blood Glucose in Outpatient Study
- Convincing Results of Solianis' Multisensor System in Home-Use Trial
- Solianis' Novel Multisensor Technology Monitors Hydration Changes in Skin - Two Patents Submitted Opening New Horizons for Cosmetic Manufacturers and Customers
- Mortara Receives Frost & Sullivan Award for DICOM ECG
- Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System
- Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
- Oridion Announces Major Medical Research and Congress Presentations
- RTX Healthcare Launch Wireless Telehealth Monitor With Built-in GSM/GPRS Mobile Phone Technology
- Ex-Menarini Executive to Lead UK for WaveSense
- Animal Health and Welfare, Public Health and Food Safety in Europe: Major Meetings in the Context of the French Presidency of the European Union
Latest News
- The Future of Financing Health Services in Africa
- Unique Digital Breast Screening Part of Offering by New Clinic
- Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa
- Unite's NHS Members Hold Day of Action on Wednesday, 3 December Over Pay
- Beat the Credit Crunch This Christmas With High Quality American Peanuts!
- Dynamics Group AG Publishes Research Report on Senetek
- diaDexus Receives CE Mark Certification for the PLAC(R) Test
- Improving Occupational Safety and Health Worldwide
- German Innovation for HIV/AIDS Diagnostics Has Been Used 2.5 Million Times in 2008
- Elsevier's EMBASE.com Partners With QUOSA
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us